Clinical peptides and PepMix™ Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, high quality peptide partner. JPT is that partner with its outstanding know-how on peptide antigen formats, peptide specifications and formulation, peptide manufacturability manufacturability and properties as well as critical analytical release testing and batch documentation warranting smooth transition from research to clinical application.
Building on our ISO 9001:2015 certified quality management system JPT established an enhanced peptide production environment that adds critical quality measures to the standard RuO (research use only) production, which are mandatory for the clinical applications of peptides and peptide pools. Resulting quality levels termed ISO PLUS Peptides and GxP Peptides focus on the more stringent requirements of immunotherapy, cell therapy, clinical immune monitoring, clinical proteomics as well as vaccine & drug development and have been approved for a variety of clinical applications.
|Incoming material inspection||X||X||X|
|Dedicated raw materials
|Certificate of analysis
|Document management & LIM-system
|Documented cleaning & calibration
|Batch documentation & CoA based on IND requirements
||X (organizational)||X (spatial)|
|Optional: certified vials
|Optional: Additional QC methods
|Optional: Impurity ID & qualification
||Report only||Report only||Report only|
Optional Analyses for Clinical Peptides & Pools
Chemical & Physical Analyses
- Peptide Purity Determination
- Peptide Molecular Weight Determination
- Peptide Sequencing
- Peptide & Building Block Structure Confirmation
- Peptide Solubility Testing
- Peptide Stability Testing
- Peptide Quantitation / Peptide Content Determination
- Amino Acid Composition
- Residual Solvent (e.g. DMF, Acetonitrile, DMSO, NMP…) Determination
- Residual Water Determination
- Residual Counter-Ion (e.g. TFA, HCl, HOAc) Determination
- Enantiomeric Integrity
Bio- & Cheminformatics
JPT’s peptides are for research use only and not intended for human in vivo application. JPT does not warrant that any peptides and peptide pools produced under GxP or ISO PLUS conditions are applicable in clinical applications (clinical grade peptides). JPT invites its customers to visit, inspect and audit our facilities to make an educated decision on whether or not peptides or peptide pools produced under GxP or ISO PLUS conditions are suited for a specific application.
- Clinical immune monitoring
- Clinical proteomics
- Adoptive cell therapy development
- Immunotherapy development
- Immune diagnostic development
Peptide-stimulated Expansion of Virus-specific T cells for Preventative Treatment After Allogeneic Stem Cell Transplantation
by R. Gary, M. Aigner, A. Gerbitz, University Hospital Erlangen, Erlangen, Germany
and A. Moosmann, Helmholz Zentrum München, Munich, Germany.
Developing Multi‐HIV Antigen Specific T Cells as a Component of a Cure Strategy
by S. Lam, C.R. Cruz and C. Bollard, Children’s National Medical Center, Washington, USA
T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant
by J. M. Keirnan, C. M. Rooney, and A. M. Leen , Baylor College of Medicine, Houston, USA
- Highest peptide purities available (up to >97%)
- Full analytical documentation (e.g. CoA, batch documention, CMC & IND support)
- Stringent quality control beyond ISO 9001:2015 regulations
- Vendor qualification, ADCF policy, line clearance, batch release and more
- Broad range of analytical options (e.g. residual solvent, stability, solubility testing, endototxin, sterility testing)
- Applicable for individual peptides, peptide libraries and peptide pools
- Site visits & audits welcome!
"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA
"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines. Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service. JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations."
Benedetto Farsaci, MD, National Cancer Institute, NIH, Bethesda, MD, USA
"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized PepMix™Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency.”
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada
Request a price
for Clinical Peptides
Boost Peptide Reliability with Peptide Analysis Services
JPT not only is the expert for peptide synthesis, but also conducts a wide variety of peptide analysis services.
NEW Cell Activation Kit: PepSup™
JPT Maintains Quality Leadership
ISO 9001:2015 Recertification
72 New Antigen Peptides & PepMixes™ available!
--> Read more News